Target Name: FSTL5
NCBI ID: G56884
Review Report on FSTL5 Target / Biomarker Content of Review Report on FSTL5 Target / Biomarker
FSTL5
Other Name(s): FSTL5 variant 1 | Follistatin like 5, transcript variant 3 | follistatin like 5 | Follistatin-like protein 5 | FSTL5_HUMAN | Follistatin-related protein 5 | Follistatin-related protein 5 (isoform c) | FSTL5 variant 3 | follistatin-like protein 5 | KIAA1263 | Follistatin like 5, transcript variant 1 | Follistatin-related protein 5 (isoform a)

FSTL5: A Potential Drug Target Or Biomarker

FSTL5, also known as FSTL5 variant 1, is a protein that is expressed in the human placenta and has been identified as a potential drug target or biomarker. The protein is a member of the FSTN family, which is known for its role in cell signaling pathways.

FSTL5 is a 14kDa protein that is expressed in the placenta, liver, and brain. It is a single-pass gene that is encoded by the FSTN gene. The protein has a molecular weight of 19.9 kDa and a calculated pI of 6.8.

FSTL5 is involved in several cellular processes, including cell signaling pathways, cell adhesion, and tissue repair. It is a component of the T-cell signaling pathway, which is involved in the regulation of cell growth, differentiation, and survival.

FSTL5 has also been shown to be involved in the regulation of the immune response, specifically in the regulation of dendritic cell development and function. Dendritic cells are a type of immune cell that play a critical role in the generation of antibodies, which are proteins that help to protect the body against infections and other harmful substances.

FSTL5 has also been shown to be involved in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. This is important for maintaining the health and function of the brain and is a potential drug target for several diseases, including Alzheimer's disease.

In addition to its role in cellular signaling pathways, FSTL5 has also been shown to be involved in the regulation of cellular processes related to cell death and injury. This is important for understanding the mechanisms of cell death and injury, as these processes can be relevant to a variety of diseases, including cancer.

FSTL5 has also been shown to be involved in the regulation of the cytoskeleton, which is the structure that gives cells shape and stability. This is important for understanding the mechanisms of cell movement and division, as these processes are critical for the growth and development of tissues.

In conclusion, FSTL5 is a protein that is expressed in the placenta and has been identified as a potential drug target or biomarker. Its involvement in cellular signaling pathways, including cell signaling pathways, cell adhesion, and tissue repair, as well as its involvement in the regulation of the immune response and the blood-brain barrier, make it a promising target for future research. Further studies are needed to determine the full extent of FSTL5's involvement in these processes and to explore its potential as a drug target or biomarker.

Protein Name: Follistatin Like 5

The "FSTL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FSTL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FTCD | FTCDNL1 | FTH1 | FTH1P1 | FTH1P10 | FTH1P11 | FTH1P12 | FTH1P2 | FTH1P20 | FTH1P22 | FTH1P24 | FTH1P3 | FTH1P4 | FTH1P5 | FTH1P7 | FTH1P8 | FTHL17 | FTL | FTLP16 | FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3